Bridging therapy for early surgery in patients on dual antiplatelet therapy after drug-eluting stent implantation

Netherlands Heart Journal

Volumn 19, Issue 10, 2011, Pages 412-417

  Marcos, E G ^a   da Fonseca, A C ^b   Hofma, S H ^a  

^a MEDICAL CENTER LEEUWARDEN   (Netherlands)

^b ISALA HOSPITAL   (Netherlands)

Author keywords

Anti platelet therapy; Bridging therapy; Drug eluting stents; Stent thrombosis

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; TIROFIBAN;

ACUTE CORONARY SYNDROME; AGED; ANEMIA; ANTICOAGULANT THERAPY; ARTICLE; BLOOD TRANSFUSION; BRIDGING THERAPY; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; CORONARY STENT; DRUG EFFECT; DRUG ELUTING STENT; DRUG HALF LIFE; DRUG SAFETY; DRUG THERAPY; EARLY INTERVENTION; FEMALE; GASTROINTESTINAL HEMORRHAGE; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PERCUTANEOUS CORONARY INTERVENTION; SIDE EFFECT; ST SEGMENT; STENT THROMBOSIS; THROMBOCYTE AGGREGATION; THROMBOCYTE COUNT; THROMBOCYTOPENIA; URINARY TRACT HEMORRHAGE;

EID: 83155181792     PISSN: 15685888     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12471-011-0197-y     Document Type: Article

References (31)

1. Sousa JE, Costa MA, Abizaid AC, et al. Four year angiographic and intravascular ultrasound follow-up of patients treated with sirolimus eluting stents. Circulation. 2005;111:2326-9.
2. Morice MC, Serruys PW, Sousa JE, et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med. 2002;346:1773-80.
3. Moses JW, Leon MB, Popma JJ, et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med. 2003;349:1315-23.
4. Stone GW, Ellis SG, Cox DA, et al. A polymer-based, paclitaxel eluting stent in patients with coronary artery disease. N Engl J Med. 2004;350:221-31.
5. Lemos PA, Serruys PW, van Domburg RT, et al. Unrestricted utilization of sirolimus-eluting stents compared with conventional bare stent implantation in the "real world": the Rapamycin-eluting Stent Evaluated at Rotterdam Cardiology Hospital (RESEARCH) registry. Circulation. 2004;109:190-5.
6. McFadden EP, Stabile E, Regar E, et al. Late thrombosis in drug eluting coronary stents after discontinuation of antiplatelet therapy. Lancet. 2004;364(9444):1519-21.
7. Iakovou I, Schmidt T, Bonizzoni E, et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drugeluting stents. JAMA. 2005;293:2126-30.
8. Rodriguez AE, Mieres J, Fernandez-Pereira C, et al. Coronary stent thrombosis in the current drug-eluting stent era: insights from the ERACI III trial. J Am Coll Cardiol. 2006;47:2057.
9. Ong AT, McFadden EP, Regar E, et al. Late angiographic stent thrombosis (LAST) events with drug-eluting stents. J Am Coll Cardiol. 2005;45:2088-92.
10. Pfisterer M, Brunner-La H, Rocca P, et al. Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus bare-metal stents. J Am Coll Cardiol. 2006;48:2584-91.
11. Smith SC, Feldman TE, Hershfeld Jr JW, et al. ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention- summary article: a report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI writing committee to update the 2001 guidelines for percutaneous coronary intervention). J Am Coll Cardiol. 2006;47:216-35.
12. Mayor S. Drug-eluting stents are safe for licensed indications, FDA says. BMJ. 2006;333:1235.
13. Silber S, Albertsson P, Aviles FF, et al. Guidelines for percutaneous coronary interventions. The Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology. Eur Heart J. 2005;26:804-47.
14. Vicenzi MN, Meislitzer T, Halaj HM, et al. Coronary artery stenting and non-cardiac surgery-a prospective outcome study. Br J Anaesth. 2006;96:686-93.
15. Kaluza GL, Joseph J, Lee JR, et al. Catastrophic outcomes of noncardiac surgery soon after coronary stenting. J Am Coll Cardiol. 2000;35:1288-94.
16. Spahn DR, Howell SJ, Delabays A, et al. Coronary stents and perioperative anti-platelet regimen: dilemma of bleeding and stent thrombosis. Br J Anaesth. 2006;96:675-7.
17. Burger W, Chemnitius JM, Kneissl GD, et al. Low-dose aspirin for secondary cardiovascular prevention-cardiovascular risks after its perioperative withdrawal versus bleeding risks with its continuation: a review and meta-analysis. J Intern Med. 2005;257:399-414.
18. Antithrombotic Trialists' Collaboration. Collaborative metaanalysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high-risk patients. BMJ. 2002;324:71-86.
19. Davies BR. Combined aspirin and clopidogrel in cataract surgical patients: a new risk factor for ocular haemorrhage? Br J Ophthalmol. 2004;88:1226-7.
20. Ernst A, Eberhardt R, Wahidi M, et al. Effect of routine clopidogrel use on bleeding complications after transbronchial biopsy in humans. Chest. 2006;129:734-7.
21. Harder S, Klinkhardt U, Alvarez JM. Avoidance of bleeding during surgery in patients receiving anticoagulant and/or antiplatelet therapy: pharmacokinetic and pharmacodynamic considerations. Clin Pharmacokinetics. 2004;43:963-81.
22. Weber AA, Braun M, Hohfeld T, et al. Recovery of platelet function after discontinuation of clopidogrel treatment in healthy volunteers. Br J Clin Pharmacol. 2001;52:333-6.
23. Albaladejo P, Marret E, Piriou V. Perioperative management of antiplatelet agents in patients with coronary stents: recommendations of a French Task Force. Br J Anaest. 2006;97(4):580-5.
24. Emmanouil SB, Subhash B, Berger PB. Perioperative management of patients with coronary stents. J Am Coll Cardiol. 2007;49:2145-50.
25. Broad L, Lee T, Conroy MB, et al. Successful management of patients with a drug-eluting coronary stent presenting for elective, non-cardica surgery. Br J Anaest. 2007;98(1):19-22.
26. Patrono C, Coller B, Dalen JE, et al. Platelet-active drugs: the relationships among dose, effectiveness, and side effects. Chest. 2001;119:39S-63S.
27. Genoni M, Zeller D, Bertel O, et al. Tirofiban therapy does not increase the risk of hemorrhage after emergency coronary surgery. J Thorac Cardiovasc Surg. 2001;122:630-2.
28. Schouten O, van Domburg RT, Bax JJ, et al. Non-cardiac surgery after coronary stenting: early surgery and interruption of antiplatelet therapy are associated with an increase in major adverse cardiac events. J Am Coll Cardiol. 2007;49: 122-4.
29. Compton PA, Zankar AA, Adesanya AO, et al. Risks of noncardiac surgery after coronary drug-eluting stent implantation. Am J Cardiol. 2006;98:1212-3.
30. Broad L, Lee T, Conroy M, et al. Successful management of patients with a drug-eluting coronary stent presenting for elective, non-cardiac surgery. Br J Anaesth. 2007;98:19-22.
31. Bizzarri F, Scolletta S, Tucci E, et al. Perioperative use of tirofiban hydrochloride (Aggrastat) does not increase surgical bleeding after emergency or urgent coronary artery bypass grafting. J Thorac Cardiovasc Surg. 2001;122:1181-5.